• Vitrue Health

  Led · Equity · Feb 2024

  Vitrue Health operates a digital musculoskeletal (MSK) health platform for workplaces that uses computer vision and biomechanical analysis to deliver workplace health assessments that are accurate, holistic and personalised. The platform aims to reduce musculoskeletal pain and help employers fulfil regulatory obligations at scale. It is used by customers including Bupa, the NHS, Hastings Direct and Campari. Led by CEO Shane Lowe, the London-based technology startup specialises in reducing musculoskeletal pain and supporting workplace health. The company raised $4M in a recent funding round, bringing its total funding to $7M. Vitrue plans to use the proceeds to grow the team and advance expansion across the US and into new European markets.

• Vee Finance

  Participated · Series B · Jan 2023

  Vee.Finance is a DeFi cross-chain lending protocol built on Avalanche that provides collateralized loans, liquidity mining, and direct leveraged trading by integrating multiple DEXs. Its smart contracts have been audited by SlowMist and CertiK, and the project scheduled mainnet launch for September 14. The protocol aims to lower the barrier for traditional finance users to access DeFi through friendlier product UX and higher capital efficiency via integrated DEX order books. After the recent financing, Vee.Finance plans to add a limit-order system that traverses integrated DEX order books for automated matching and execution, expand support to additional public chains based on community demand, and integrate decentralized derivatives trading. The team also launched a pre-mainnet airdrop to reward users who tested the Farm feature; the airdrop totals 240,000 VEE and will be distributed to the top 4,000 users by Farm yield (snapshot on Sept 14, 16:00; event began Sept 12, 10:00).

• HIMS

  Participated · Series A · Nov 2017

  Hims is a direct-to-consumer wellness startup that sells sexual wellness products, skin care, and hair-loss treatments, and has incorporated a women's brand, Hers. The company offers erectile dysfunction medication, prescription birth-control pills and Addyi for hypoactive sexual desire disorder. Hims officially launched just over one year ago and has pursued rapid product expansion into women's health alongside its flagship men's offerings. It is consumer-facing and marketed heavily, which has driven fast brand recognition. Financially, the company had previously raised $197 million and entered this new financing round with significant cash on hand. Negotiations for the latest round reportedly took months, with some investors balking at valuation and the company passing on several viable term sheets. Hims is a San Francisco-based online men's health platform that discretely ships men’s health products and prescription medications. Customers complete a digital assessment that a network of doctors reviews to prescribe treatments; the platform also includes a telemedicine component. It partners with mail-order pharmacies to secure lower prices and offers products including a cold sore kit (valacyclovir), multiple hair-loss treatments, erectile dysfunction medications, and an anti-aging cream launching this month. The company positions its service as a cheaper, more accessible alternative to traditional doctor visits. Hims launched in November 2017. According to Crunchbase it has raised $57 million to date. The new capital will be used to grow its prescription drug business. Hims launched as a men’s wellness brand focused initially on hair loss, selling direct-to-consumer kits that bundle prescription medications and supplements. Its $40 kit includes finasteride (a generic of Propecia), minoxidil, a DHT shampoo, and supplements aimed at thicker hair, stronger nails, and smoother skin. Products arrive in elegant, sustainable packaging and the company leverages online/telemedicine-enabled distribution to simplify access to prescriptions. Hims positions hair care as the first vertical and plans to expand into sexual wellness, cholesterol wellness, and other long-term men’s health categories. The startup was incubated at the San Francisco–based studio Atomic, is led by CEO Andrew Dudum, and is a roughly 10-person company. Financially, Hims recently closed a $7 million Series A to support its growth and product expansion.

No current team members are available.